Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Foghorn Therapeutics's quarterly market cap
declined
from Dec. 2025 ($305.95 Mil) to Mar. 2026 ($280.63 Mil) but then
increased
from Mar. 2026 ($280.63 Mil) to Jun. 2026 ($286.52 Mil).
Foghorn Therapeutics's annual market cap
declined
from Dec. 2023 ($272.72 Mil) to Dec. 2024 ($262.40 Mil) but then
increased
from Dec. 2024 ($262.40 Mil) to Dec. 2025 ($305.95 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Foghorn Therapeutics's Enterprise Value for Today is $272.81 Mil.
Foghorn Therapeutics (NAS:FHTX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Foghorn Therapeutics Market Cap Related Terms
Foghorn Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Foghorn Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Foghorn Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Foghorn Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Foghorn Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Foghorn Therapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Foghorn Therapeutics (FHTX) has a Market Cap of $397.29 Mil as of Aug. 26, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Foghorn Therapeutics and its competitors. According to the industry distribution chart, Foghorn Therapeutics ranks #468 out of 1421 companies in the Biotechnology industry, placing it in the top 32.9%.
Is Foghorn Therapeutics' Market Cap too high?
Foghorn Therapeutics' current Market Cap is $397.29 Mil. The Biotechnology industry median Market Cap is 123.85. Foghorn Therapeutics' value of $397.29 Mil is 220.8% above this industry median. Based on the distribution chart, Foghorn Therapeutics ranks #468 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Foghorn Therapeutics has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Foghorn Therapeutics' Market Cap compare to NWBO and FATE?
According to the Biotechnology industry distribution chart, Foghorn Therapeutics ranks #468 out of 1421 companies for Market Cap. This puts Foghorn Therapeutics in the upper half of its industry. The industry median Market Cap is 123.85. Foghorn Therapeutics' value of $397.29 Mil is 220.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 123.85, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Foghorn Therapeutics's current Market Cap of $397.29 Mil is 220.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Foghorn Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 123.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Foghorn Therapeutics's current Market Cap is $397.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Foghorn Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Foghorn Therapeutics (FHTX) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.32, compared to a current price of $6.69 — trading 25.8% above its estimated fair value. The current Market Cap is $397.29 Mil and 220.8% above the Biotechnology industry median of 123.85. Foghorn Therapeutics' overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Foghorn Therapeutics (FHTX), the current Market Cap is $397.29 Mil as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Foghorn Therapeutics (FHTX) Overvalued in 2026?
Based on GuruFocus' analysis, Foghorn Therapeutics stock appears to be overvalued.
The current stock price of $6.69 is trading 25.8% above its estimated GF Value™ of $5.32.
GuruFocus considers Foghorn Therapeutics to be Modestly Overvalued.
Key valuation signals for FHTX:
Market Cap: $397.29 Mil
GF Value™: $5.32 vs. price of $6.69 (25.8% above fair value)
Industry Position: 220.8% above the Biotechnology median (#468 of 1421)
No single metric tells the full story. See the FHTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.
67GF Score
Get the complete analysis for FHTX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FHTX has been successfully added to your 
